1. Taiwan, Province of China Stocks

  2. •

    Consumer Defensive

  3. •

    Household & Personal Products
EOS, Inc.

EOS, Inc.

EOSS
EOS, Inc.US flagOther OTC
0.00
USD
- -
- -
60,478.00Market Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
4.49
23.55
27.73
32.63
26.14
0.01
- -
- -
- -
Basic EPS, GAAP
- -
-4.11
13.89
16.05
15.41
-10.4
-0.01
-0.01
- -
- -
Free Cash Flow per Basic Share
- -
-1.86
0.17
0.17
3.75
-4.92
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-5.75
8.28
24.33
37.79
24.33
0.01
-0.01
-0.01
- -
Tangible Book Value per Share
- -
-4.3
9.88
25.56
39.58
28.9
0.01
-0.01
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
77
182
220
372
Sales/Revenue/Turnover
- -
- -
2
2
2
2
1
1
- -
- -
Operating Margin (%)
- -
-89.43
58.36
57.02
48.41
-38.3
-206.19
-294.48
-260.27
-758.4
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
1
1
1
-1
-1
-2
-1
-1
Effective Tax Rate (%)
- -
- -
4.27
1.7
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-91.59
59.01
57.89
47.25
-39.8
-212.46
-286.7
-211.27
-452.98
Working Capital
- -
- -
1
2
3
2
1
-1
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
1
2
3
2
1
-1
-1
-1
Return on Invested Capital (%)
- -
- -
421.76
84.91
49.08
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
1,042.77
98.44
50.94
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
98.44
51.36
-34.62
-81.41
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
605
605
605
Market Capitalization
56
12
4

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-34.19%
16.08%
Free Cash Flow
- -
431.81%
73.54%
Net Income, GAAP
- -
-24%
-66.48%
Sales/Revenue/Turnover
- -
-17.7%
-54.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
1
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.01
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
He-Siang Yang
Full Time Employees
9
Sector
Consumer Defensive
Industry
Household & Personal Products
Address
No. 162, Zhongshan North Road Taipei Taiwan, Province of China 10452
IPO Date
Jan 6, 2017
CIK
0001651958
Website
eosinc999.us
Similar Companies
Duni AB (publ) (DUNIY)
Pola Orbis Holdings Inc. (4927.T)
Ador Multiproducts Limited (ADORMUL.BO)
The Stephan Co. (SPCOQ)
Jourdeness Group Limited (4190.TW)
The Estée Lauder Companies Inc. (0JTM.L)
Business
EOS, Inc. (EOSS) operates as a distributor of biotechnology and consumer health products primarily in the Asia Pacific region, including China, Taiwan, Singapore, and Malaysia. The company offers nutrition supplements targeting immune system support, kidney disease, and cancer prevention with over 50 international medical patents and more than 30 product technology patents; skin care products such as masks and serums; water purifiers; and ginsenosides supplements marketed under the Bodywafer brand. Founded in 2015 and headquartered at No. 5, Qingdao East Road, 5F-1, Taipei City, Taiwan, EOS, Inc. serves channel partners through direct sales and provides comprehensive training via onsite seminars and online webinars. Recent developments include a June 2024 partnership with Kang Qing Song Health Innovation & Technology Co. for cellular health products; a cooperation agreement with ZHONGKEZHONGLUAN (Guangdong) Holdings (Group) Limited to expand biotechnology offerings; an August 2023 appointment of Zongjiang He as acting chief financial officer following He-Siang Yang's resignation from that role; the appointment of new energy technology consultants to advance green energy initiatives; estimated over $40 million in tax-inclusive sales for Q1 2024; and ongoing efforts toward financial consolidation, internal control enhancements, and Nasdaq Capital Market listing preparation through negotiations for acquisitions of profitable companies.